• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Why Isn't Biogen Stock Soaring After This Major FDA Approval?

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jul 13, 2023 at 10:33: AM
via
  • The FDA gave full approval for Alzheimer's drug Leqembi in July.
  • Despite the positive news, Biogen's stock didn't take off.
  • That's because the company still faces some significant headwinds.

article source
 

<



Similar threads

cafead
Why Biogen&#039;s Stock Isn&#039;t Soaring Since Its Alzheimer&#039;s Drug Got Approval
Replies
0
Views
116
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Eli Lilly&#039;s Alzheimer&#039;s Drug Obtains FDA Approval. Here&#039;s Why the Stock Isn&#039;t Taking Off.
Replies
0
Views
34
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA commissioner on drug approvals: The problem isn&#039;t innovation or speed
Replies
0
Views
272
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Takeda touts positive first-line leukemia results — but isn&#039;t quite ready to reveal...
Replies
0
Views
168
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Two Aurinia execs are out — and CRISPR’s operations chief isn&#039;t far behind
Replies
0
Views
244
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote